Wire · opportunities
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 August 2026 · Fusion42 review
Regeneron has received FDA approval for Pasatru (garetosmab), becoming the second drug approved to treat fibrodysplasia ossificans progressiva (FOP) in the U.S., setting up competition with Ipsen's Sohonos which was approved in 2023.
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 19 Aug 2026 and 31 Aug 2026.
◆ ◆ The Wire takeaway
You face a new competitor with FDA-approved treatment for FOP creating pressure to differentiate or pivot. Look for opportunities to engage clinicians who value treatment flexibility and patient mobility support.
◆ Coverage
8 sources · first reported 19 Aug 2026 · latest 31 Aug 2026
◆ Topics